Anecortave acetate: A new approach for the medical treatment of glaucoma

Amy Lewis Hennessy, Alan L. Robin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The medical management of glaucoma is often compromised by patients' nonadherence with prescribed topical therapy - both the ability to execute eye drop administration and persistency of medication use. This can be made more complex in patients who are taking multiple systemic medi-cations and multiple medications to lower IOP. The consequence of inadequate treatment arising from patient nonadherence is disease progression, with permanent and irreversible loss of visual function. The Early Manifest Glaucoma Treatment Study (EMGTS) found that among individuals treated and closely monitored for their glaucoma, 57% progressed in a 5-year period. In 2008, Urquhart described noncompliance, nonabsorption, and nonresponse as possibilities for disease progression despite use of prescribed medications. It may be that part of the reason for progression in glaucoma is poor adherence to prescribed therapy.

Original languageEnglish (US)
Title of host publicationThe Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care
PublisherSpringer New York
Pages989-993
Number of pages5
ISBN (Print)9780387766997
DOIs
StatePublished - 2010

Fingerprint

Glaucoma
Patient Compliance
Disease Progression
Aptitude
Ophthalmic Solutions
Therapeutics
Cations
anecortave acetate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hennessy, A. L., & Robin, A. L. (2010). Anecortave acetate: A new approach for the medical treatment of glaucoma. In The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care (pp. 989-993). Springer New York. https://doi.org/10.1007/978-0-387-76700-0_89

Anecortave acetate : A new approach for the medical treatment of glaucoma. / Hennessy, Amy Lewis; Robin, Alan L.

The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care. Springer New York, 2010. p. 989-993.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hennessy, AL & Robin, AL 2010, Anecortave acetate: A new approach for the medical treatment of glaucoma. in The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care. Springer New York, pp. 989-993. https://doi.org/10.1007/978-0-387-76700-0_89
Hennessy AL, Robin AL. Anecortave acetate: A new approach for the medical treatment of glaucoma. In The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care. Springer New York. 2010. p. 989-993 https://doi.org/10.1007/978-0-387-76700-0_89
Hennessy, Amy Lewis ; Robin, Alan L. / Anecortave acetate : A new approach for the medical treatment of glaucoma. The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care. Springer New York, 2010. pp. 989-993
@inbook{305da4922994473c8443c7f88423699d,
title = "Anecortave acetate: A new approach for the medical treatment of glaucoma",
abstract = "The medical management of glaucoma is often compromised by patients' nonadherence with prescribed topical therapy - both the ability to execute eye drop administration and persistency of medication use. This can be made more complex in patients who are taking multiple systemic medi-cations and multiple medications to lower IOP. The consequence of inadequate treatment arising from patient nonadherence is disease progression, with permanent and irreversible loss of visual function. The Early Manifest Glaucoma Treatment Study (EMGTS) found that among individuals treated and closely monitored for their glaucoma, 57{\%} progressed in a 5-year period. In 2008, Urquhart described noncompliance, nonabsorption, and nonresponse as possibilities for disease progression despite use of prescribed medications. It may be that part of the reason for progression in glaucoma is poor adherence to prescribed therapy.",
author = "Hennessy, {Amy Lewis} and Robin, {Alan L.}",
year = "2010",
doi = "10.1007/978-0-387-76700-0_89",
language = "English (US)",
isbn = "9780387766997",
pages = "989--993",
booktitle = "The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care",
publisher = "Springer New York",

}

TY - CHAP

T1 - Anecortave acetate

T2 - A new approach for the medical treatment of glaucoma

AU - Hennessy, Amy Lewis

AU - Robin, Alan L.

PY - 2010

Y1 - 2010

N2 - The medical management of glaucoma is often compromised by patients' nonadherence with prescribed topical therapy - both the ability to execute eye drop administration and persistency of medication use. This can be made more complex in patients who are taking multiple systemic medi-cations and multiple medications to lower IOP. The consequence of inadequate treatment arising from patient nonadherence is disease progression, with permanent and irreversible loss of visual function. The Early Manifest Glaucoma Treatment Study (EMGTS) found that among individuals treated and closely monitored for their glaucoma, 57% progressed in a 5-year period. In 2008, Urquhart described noncompliance, nonabsorption, and nonresponse as possibilities for disease progression despite use of prescribed medications. It may be that part of the reason for progression in glaucoma is poor adherence to prescribed therapy.

AB - The medical management of glaucoma is often compromised by patients' nonadherence with prescribed topical therapy - both the ability to execute eye drop administration and persistency of medication use. This can be made more complex in patients who are taking multiple systemic medi-cations and multiple medications to lower IOP. The consequence of inadequate treatment arising from patient nonadherence is disease progression, with permanent and irreversible loss of visual function. The Early Manifest Glaucoma Treatment Study (EMGTS) found that among individuals treated and closely monitored for their glaucoma, 57% progressed in a 5-year period. In 2008, Urquhart described noncompliance, nonabsorption, and nonresponse as possibilities for disease progression despite use of prescribed medications. It may be that part of the reason for progression in glaucoma is poor adherence to prescribed therapy.

UR - http://www.scopus.com/inward/record.url?scp=84878020052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878020052&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-76700-0_89

DO - 10.1007/978-0-387-76700-0_89

M3 - Chapter

AN - SCOPUS:84878020052

SN - 9780387766997

SP - 989

EP - 993

BT - The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care

PB - Springer New York

ER -